The short version of research chemical fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-09. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Other clinically significant pathologies involving astrocytes include astrogliosis and astrocytopathy. Examples of these include multiple sclerosis, anti-AQP4+ neuromyelitis optica, Rasmussen's encephalitis, Alexander disease, and amyotrophic lateral sclerosis. Studies have shown that astrocytes may be implied in neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Stuttering and amyotrophic lateral sclerosis, and in acute brain injuries, such as intracerebral hemorrhage and traumatic brain injury.
=== Radiotherapy === Radiotherapy is used mostly for focal type of NM due to the nature of damage and success rate associated with the treatment. Radiotherapy targets the tumor and destroys the collective tissues of cancerous cells. Proton therapy, which delivers radiation via charged protons rather than X-rays, has recently shown promise as an effective treatment for leptomeningeal disease.
Implement specific measures to detect and deter money laundering and the financing of terrorist activities and to facilitate the investigation and prosecution of money laundering and terrorist financing offences including: Mandatory report requirement of suspicious financial transaction, large electronic fund transfers, and all large cash transactions, establishment of record keeping and client identification requirements for financial service providers and other persons that engage in businesses, professions or activities that are susceptible to being used for money laundering and the financing of terrorist activities. Fulfill Armenia's commitments to participate in the global fight against money laundering and terrorist financing. Towards this end, a special agency called Interagency Task Force 4 was created, which is responsible for the continual effective and cooperative activity in the sphere of fraudulence connected with money laundering, credit cards as well as terrorist financing in Armenia. To respond to the threat posed by organized criminals and terrorists by providing law enforcement officials with the information they need to deprive criminals and terrorists of the proceeds of their criminal activities and funds to support terrorist activities, while ensuring that appropriate safeguards are put in place to protect privacy of persons with respect to personal information.
Sources: en.wikipedia.org
ASBMB Award for Exemplary Contributions to Education ASBMB Leadership Awards ASBMB–Merck Award ASBMB Young Investigator Award Avanti Award in Lipids Bert and Natalie Vallee Award in Biomedical Science DeLano Award for Computational Biosciences Earl and Thressa Stadtman Distinguished Scientist Award Earl and Thressa Stadtman Young Scholar Award Herbert Tabor Research Award Mildred Cohn Award in Biological Chemistry - The Mildred Cohn Award in Biological Chemistry was established in 2013 to honor the scientific achievements of Mildred Cohn. Cohn was the first female president of the society, in 1978. The award of $5,000 is presented annually to a scientist who has made substantial advances in understanding biological chemistry using innovative physical approaches. The recipient is expected to deliver the Mildred Cohn Award lecture at the annual meeting. Ruth Kirschstein Diversity in Science Award The Alice and C. C. Wang Award in Molecular Parasitology Walter A. Shaw Young Investigator Award in Lipid Research William C. Rose Award
The function of intrinsic termination is to signal for the dissociation of the ternary elongation complex (TEC), which ends transcription and releases RNA polymerase and its associated cofactors as well as the new RNA transcript. Intrinsic termination occurs independently of the protein Rho, in contrast to Rho-dependent termination, where the Rho protein must act on the RNA polymerase in order for it to dissociate from the transcription complex. Here, there is no extra protein and the transcript forms its own loop structure. Intrinsic termination thus regulates the level of transcription as well, determining how many polymerases can transcribe a gene over a given period of time, and can help prevent interactions with neighboring chromosomes.
=== 1997 Georgia === In 1997, several Georgian soldiers suffered radiation poisoning and burns. They were eventually traced back to training sources left abandoned, forgotten, and unlabelled after the dissolution of the Soviet Union. One was a caesium-137 pellet in a pocket of a shared jacket that released about 130,000 times the level of background radiation at a 1-metre (3-foot) distance.
Sources: en.wikipedia.org
== Discovery == In 2004 Linda B. Buck and Richard Axel won the Nobel Prize in Physiology or Medicine for their work on olfactory receptors. In 2006, it was shown that another class of odorant receptors – known as trace amine-associated receptors (TAARs) – exist for detecting volatile amines. Except for TAAR1, all functional TAARs in humans are expressed in the olfactory epithelium. A third class of olfactory receptors known as vomeronasal receptors has also been identified; vomeronasal receptors putatively function as pheromone receptors. As with many other GPCRs, there is still a lack of experimental structures at atomic level for olfactory receptors and structural information is based on homology modeling methods. In 2023 the structure of OR51E2 was found, the first elucidation of the structure of any human olfactory receptor. The limited functional expression of olfactory receptors in heterologous systems, however, has greatly hampered attempts to deorphanize them (analyze the response profiles of single olfactory receptors) This was first completed by genetically engineered receptor, OR-I7 to characterize the "odor space" of a population of native aldehyde receptors.
The last two gates were directly opposite the Red Square, while the Konstantino-Eleninsky gate was located behind Saint Basil's Cathedral. The Russian famine of 1601–1603 killed possibly 100,000 people in Moscow. Between 1610 and 1612, troops of the Polish–Lithuanian Commonwealth occupied Moscow, as its ruler Sigismund III tried to take the Russian throne. In 1612, Nizhny Novgorod and other Russian cities, led by prince Dmitry Pozharsky and Kuzma Minin, rose against the Polish occupants, besieged the Kremlin, and expelled them. In 1613, the Zemsky Sobor (lit. 'assembly of the land'; parliament) elected Michael Romanov as tsar, establishing the Romanov dynasty. The 17th century witnessed several uprisings—such as the liberation of Moscow from Polish–Lithuanian invaders (1612), the Salt Riot (1648), the Copper Riot (1662), and the Moscow uprising of 1682. During the first half of the 17th century, Moscow's population doubled from 100,000 to 200,000, and it expanded beyond its ramparts in the latter part of the century. In the middle of the 17th century, 20% of Moscow suburban inhabitants came from the Grand Duchy of Lithuania, having been driven from their homeland by Muscovite invaders. By 1682, 692 households were established north of the ramparts—by Ukrainians and Belarusians abducted from their hometowns during the Russo-Polish War of 1654–1667. These new outskirts became known as the Meshchanskaya sloboda (settlement), after the Ruthenian term meshchane meaning "town people".
== Clinical significance == Patients with mutations in the GSS gene develop glutathione synthetase (GSS) deficiency, an autosomal recessive disorder. Patients develop a wide range of symptoms depending on the severity of the mutations. Mildly affected patients experience a compensated haemolytic anaemia because mutations affect stability of the enzyme. Moderately and severely affected individuals have enzymes with dysfunctional catalytic sites, rendering it unable to participate in detoxification reactions. Physiological symptoms include metabolic acidosis, neurological defects, and increased susceptibility to pathogenic infections. Treatment of individuals with glutathione synthetase deficiency generally involve therapeutic treatments to address mild to severe symptoms and conditions. In order to treat metabolic acidosis, severely affected patients are given large amounts of bicarbonate and antioxidants such as vitamin E and vitamin C. In mild cases, ascorbate and N-acetylcysteine have been shown to increase glutathione levels and increase erythrocyte production. Bbecause glutathione synthetase deficiency is so rare, it is poorly understood. The disease also appears on a spectrum, so it is even more difficult to generalize among the few cases that occur.
Moxidectin has a longer half-life than ivermectin and may eventually supplant ivermectin as it is a more potent microfilaricide, but there is a need for additional clinical trials, with long-term follow-up, to assess whether moxidectin is safe and effective for treatment of nematode infection in children and women of childbearing potential. There is tentative evidence that ivermectin kills bedbugs, as part of integrated pest management for bedbug infestations. However, such use may require a prolonged course of treatment which is of unclear safety.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.